A recent study by researchers at the University of Virginia suggests previously unknown links between the body's immune system and the brain. According to Cure Alzheimer's Fund Research Consortium chairman Dr. Rudy Tanzi, these findings could be "absolutely game-changing" in the field of Alzheimer's research once confirmed.
David Holtzman, M.D., member of the Cure Alzheimer’s Fund Research Consortium, will receive the 2015 Carl and Gerty Cori Faculty Achievement Award from his home institution, Washington University in St. Louis. The award goes to faculty members who “embody the ideals of individual and collaborative excellence” and “have made significant contributions to their fields,” according to Washington University Chancellor Mark S. Wrighton.
Every year the Cure Alzheimer’s Fund (CAF) Research Consortium members get together with the Board of Directors to discuss their respective research projects, refine their strategy, and leave with a clear mission. This year was no exception.
By the time she was 17, Alexandra Newton had lived in seven different countries and had mastered four different languages. But her family was not surprised when she chose to pursue a career in biochemistry instead of language arts.
Rudy Tanzi, Ph.D., chair of the Cure Alzheimer's Fund Research Consortium, was named one of TIME Magazine's '100 Most Influential People of 2015' in a list published earlier this week.
Tanzi has long been known for his pioneering work in Alzheimer's disease research, especially Alzheimer's genetics. He made an especially important contribution to the field in 2014 with his lab's "Alzheimer's in a Dish" breakthrough, a tool that will be used to enhance our understanding of the disease and accelerate drug discovery.
For the fourth year in a row, Cure Alzheimer’s Fund has received a 4-star rating – the highest possible – from watchdog organization Charity Navigator. Charity Navigator rates over 8,000 nonprofits on many aspects of their accountability, transparency and fiscal responsibility.
As reported recently in the New York Times (Business Day, March 20, 2015, “Biogen Reports Its Alzheimer’s Drug Sharply Slows Cognitive Decline”) and other media, the pharmaceutical company Biogen has announced impressive results in a Phase I “human safety” trial of a new drug designed to treat — and possibly prevent — Alzheimer’s disease.
In a recent news piece, Massachusetts General Hospital (MGH) chose to highlight Cure Alzheimer's Fund's support of research through the lab of Dr. Rudy Tanzi.
MGH praises the venture capital approach taken by CAF co-founders Jeff and Jacqui Morby, enabling researchers like Tanzi to take risks and pursue "paradigm changing" studies. And the risks have paid off: According to MGH, the scientific results brought about by CAF-funded research are "nothing short of game changing, as Mass General researchers resolve some long-unanswered questions about how Alzheimer’s disease develops."